Turn Therapeutics (TTRX) is having a good Tuesday. The biotech company announced that a planned interim analysis of its Phase 2 trial for GX-03, a treatment for atopic dermatitis (the fancy name for eczema), has led to some smart tweaks to the study design — and an expansion of the patient population. Investors liked what they heard, sending shares up 13.13% to $8.69.

The interim analysis, which reviewed data from the first 50 patients under the watch of an Independent Data Monitoring Committee, confirmed that GX-03 is showing signs of working. The company said the multi-week review finalized the Stage 2 protocol by refining patient selection, disease stratification, efficacy endpoints, and statistical methodology. In plain English: they looked at the early data, figured out what was working, and adjusted the trial to give the drug its best shot at proving it works.

One of the key findings was that Week 4 produced the earliest and clearest separation between GX-03 and the vehicle control (the placebo, essentially). So the company added Week 4 efficacy endpoints to the final study design. They also spotted that baseline pruritus severity — how itchy patients were at the start — could be a useful biomarker for predicting treatment response. That's the kind of insight that can make a trial more efficient and informative.

But the biggest change? The patient population is getting broader. The interim data showed treatment activity among patients with baseline EASI scores (Eczema Area and Severity Index) ranging from 1.1 to 7.0 — a group generally classified as having mild-to-moderate atopic dermatitis. Within that subgroup, GX-03 demonstrated improvements in Week 4 vIGA-AD Success and complete disease clearance at both Week 4 and Week 8 compared with the vehicle treatment.

So the final Stage 2 design will continue evaluating patients with greater inflammatory burden while expanding enrollment to include patients across the full baseline EASI spectrum. The revised trial will enroll approximately 120 to 135 patients. The company expects to complete enrollment in the fourth quarter of 2026 and said it has sufficient capital to support the study and planned operations through the third quarter of 2027.

Safety-wise, things look clean: no treatment-related serious adverse events, tolerability issues, or study discontinuations have been reported in either treatment group. That's always a good sign.

For a small biotech, this kind of data-driven flexibility is a big deal. It shows the company is paying attention to what the data is telling them and adjusting accordingly — rather than blindly plowing ahead with a rigid plan. And the market is rewarding that discipline today.